Blueprint
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
February
09, 2017
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
15 Adam
Street
London, England WC2N 6LA
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant in
connection with Rule 12g3-2 (b) : 82- n/a.
9
February 2017
DIRECTORATE
CHANGES
Smith
& Nephew plc (LSE:SN, NYSE:SNN), the global medical technology
business, today announces, in accordance with Listing Rule
9.6.11(2) R, that Brian Larcombe will retire as Senior Independent
Director and Non-Executive Director at the conclusion of the Annual
General Meeting on 6 April 2017.
Following the
Annual General Meeting on 6 April 2017, and subject to his
re-election as a Director of Smith & Nephew plc at the Annual
General Meeting, Ian Barlow will be appointed as the Senior
Independent Non-Executive Director, in place of Brian
Larcombe.
On 1
March 2017, Ian Barlow will step down as Chairman of the Audit
Committee and Robin Freestone will be appointed Chairman of the
Audit Committee in his place.
Roberto
Quarta, Chairman, said
"Brian
Larcombe has served Smith & Nephew for many years, as our
Senior Independent Director since 2014, and as a member of the
Audit, Nomination & Governance and Remuneration Committees. We
will miss his great wisdom and experience. On behalf of the whole
Board I thank him for his service and wish him well for the
future."
ends
Enquiries
|
Investors
|
|
|
|
Ingeborg
ØieSmith & Nephew
|
+44 (0)
20 7960 2285
|
|
|
Media
|
|
|
|
Charles
ReynoldsSmith & Nephew
|
+44 (0)
20 7401 7646
|
|
|
Matthew
Cole / Debbie ScottFTI Consulting
|
+44 (0)
20 3727 1000
|
|
|
|
|
|
|
|
|
|
|
|
About
Smith & Nephew
Smith
& Nephew is a global medical technology business dedicated to
helping healthcare professionals improve people's lives. With
leadership positions in Orthopaedic
Reconstruction, Advanced Wound
Management, Sports Medicine
and Trauma
& Extremities, Smith & Nephew has around 15,000
employees and a presence in more
than 100 countries. Annual sales in 2015 were more than $4.6
billion. Smith & Nephew is a member of the FTSE100 (LSE:SN,
NYSE:SNN).
For
more information about Smith & Nephew, please visit our website
www.smith-nephew.com, follow @SmithNephewplc
on Twitter or visit SmithNephewplc
on Facebook.com.
Forward-looking
Statements
This
document may contain forward-looking statements that may or may not
prove accurate. For example, statements regarding expected revenue
growth and trading margins, market trends and our product pipeline
are forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊
Trademark of Smith & Nephew. Certain marks registered US Patent
and Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: February
09, 2017
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary